News Conference News AHA 2023 Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study Michael O'Riordan November 13, 2023
News Conference News AHA 2023 New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference? Shelley Wood November 13, 2023
News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Conference News AHA 2023 Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH Caitlin E. Cox November 12, 2023
News Conference News AHA 2023 Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics Todd Neale November 11, 2023
News Conference News AHA 2023 DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI Shelley Wood November 11, 2023
News Conference News AHA 2023 Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients Caitlin E. Cox November 07, 2023
News Opinion Editor's Corner AHA 2023 What’s Going to Be Hot at AHA 2023 Shelley Wood November 07, 2023
News Conference News AHA 2022 Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START Todd Neale November 14, 2022
News Conference News AHA 2022 Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study Michael O'Riordan November 07, 2022
News Conference News AHA 2022 Botulinum Toxin Injections No Help for Postoperative AF: NOVA Yael L. Maxwell November 07, 2022
News Conference News AHA 2022 ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD Shelley Wood November 06, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis Yael L. Maxwell November 05, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News AHA 2022 TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF Todd Neale November 05, 2022
News Conference News AHA 2022 Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions Yael L. Maxwell November 01, 2022
News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Conference News AHA 2021 An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops Shelley Wood November 15, 2021